DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
Posted inHematology-Oncology news

DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results

In older adults (≥60 years) with non‑adverse‑risk AML enrolled in NCRI AML18, daunorubicin/cytarabine plus fractionated gemtuzumab (DAGO2) produced higher early MRD‑negative CR rates and superior 3‑year EFS and OS versus CPX‑351, with particular molecular subgroups showing no benefit or harm from CPX‑351.
DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
Posted inHematology-Oncology news

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups including NPM1 and FLT3 mutations.
Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
Posted inHematology-Oncology news

Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations

Preclinical work shows that combining the BCL‑2 inhibitor venetoclax with the FLT3 inhibitor gilteritinib produces deep, reproducible anti‑leukemia activity in FLT3‑mutant, BCL11B‑activated lineage‑ambiguous leukemias. BH3 profiling and single‑cell transcriptomics reveal mechanisms of resistance and biology of residual cells, supporting rapid clinical evaluation.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.
Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations
Posted inCardiology Clinical Updates Neurology news

Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations

Emerging cohort evidence reveals myocardial infarction significantly elevates late-onset epilepsy risk, with late-onset epilepsy also predicting subsequent myocardial infarction and vascular mortality, underscoring shared systemic vascular pathology and implications for integrated vascular risk management.
Personalized Prehabilitation Before Major Surgery Modulates the Immune System and Lowers Complications: Translating Fitness Into an ‘Immunome’ Signal
Posted inAnesthesiology General Surgery news

Personalized Prehabilitation Before Major Surgery Modulates the Immune System and Lowers Complications: Translating Fitness Into an ‘Immunome’ Signal

A randomized trial found personalized, remotely coached prehabilitation improved preoperative physical and cognitive function, produced distinct immunologic dampening of inflammatory signaling, and reduced moderate-to-severe postoperative complications compared with a paper-based standard program.
Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery
Posted inDiabetes & Endocrinology General Surgery news

Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery

A large multicenter cohort shows that both diagnosed and previously unrecognized diabetes (by HbA1c) are common in general surgery patients and independently linked to higher 30‑day complications, readmissions, and mortality—supporting routine preoperative HbA1c assessment and individualized perioperative glycemic strategies.
Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT
Posted inGeneral Surgery news Oncology

Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT

The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestly higher blood loss.
Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort
Posted innews Psychiatry Public Health

Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort

A longitudinal, nationally representative cohort study found that within-person transition from current to former cigarette smoking was associated with a 30–43% higher odds of sustained recovery from other substance use disorders, supporting integration of smoking cessation into SUD care.
GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III
Posted inInfectious Diseases news Public Health

GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III

A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide) with once‑daily lumefantrine and shows promise against partially resistant strains and gametocytes.